Sionna Therapeutics Q2 net loss widens to $29.9 million from $18.1 million
Sionna Therapeutics reported a second-quarter 2026 net loss of $29.9 million, up from $18.1 million a year earlier, as research and development and general and administrative expenses both rose. The company had $268.3 million in cash, cash equivalents and marketable securities at June 30, 2026, which it expects will fund operations into 2028, and it reiterated that topline data from two clinical trials are on track for summer 2026.
Key points
- Net loss was $29.9 million for Q2 2026, compared with $18.1 million for Q2 2025.
- Research and development expenses rose to $21.9 million from $15.4 million; general and administrative expenses rose to $10.6 million from $6.5 million.
- Cash, cash equivalents and marketable securities totaled $268.3 million at June 30, 2026, down from $310.3 million at December 31, 2025.
- Topline data from the PreciSION CF Phase 2a trial of SION-719 and the Phase 1 dual combination trial of SION-451 are expected in summer 2026.
The filing
Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.